MARTIN Ludovic
Angers, 49933, France
NCT Number: NCT05246189
Pseudoxanthoma elasticum (PXE) is a rare, autosomal recessive genetic disease characterized by progressive calcification and fragmentation of elastic fibers in connective tissues. PXE primarily affect the skin, retina and arterial walls. Given the age of onset and progression of the disease, the consequences of PXE affect a large number of patients of working age and are therefore likely to have an impact on their professional career and job retention.
To our knowledge, there are no studies on the occupational impact of PXE.
Looking for future studies?
Notify Me18 year–64 year
All sexes
Observational
Angers, 49933, France
This is an epidemiological, descriptive and analytical, cross-sectional, monocentric study, carried out by telephone questionnaire on the national cohort of the PXE Reference Center in the Dermatology Department of the Angers University Hospital.
Eligible subjects will be pre-selected by the study investigators on the basis of the medical file. A letter of information about the study will be sent to all the pre-selected eligible patients, with the exception of patients who have expressed an objection to the processing of their data for research purposes.
The investigators will contact eligible patients by telephone approximately 2 weeks after the mailing of the information letter. During this telephone call, the investigator will answer any questions the patient may have about the study and will collect the patient's non-objection to participate in the study and their responses to the questionnaire.
In the absence of a validated questionnaire to meet the objectives of the study, a questionnaire was created.
This questionnaire was tested in order to verify its feasibility and clarity. Medical data (age at diagnosis, age at referral to the Reference Centre, organ damage and clinical manifestations present at the time of the survey, treatments, etc.) will be collected from the medical file and the answers to the questionnaire will be collected by telephone on paper. Data will be collected in a coded manner. A correspondence list will be kept, under the responsibility of the principal investigator.
No follow-up of patients is planned by the study.
The results of this study should make it possible to provide new data on the impact of PXE on the career path and job retention of patients, as well as the medical reasons linked to it. It should also make it possible to improve knowledge on the experience of the consequences of PXE for patients in the workplace, as well as the actors and tools for job retention mobilised in these situations. All of these elements should make it possible to improve the prevention of the professional deintegration of PXE patients, in particular by setting up systematic and early management of patient-workers presenting a declared PXE.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Eligible subjects will be pre-selected by the study investigators on the basis of the medical file. A letter of information about the study will be sent to all the pre-selected eligible patients, with the exception of patients who have expressed an objection to the processing of their data for research purposes during their treatment.
The investigators will contact eligible patients by telephone approximately 2 weeks after the mailing of the information letter. During this telephone call, the investigator will answer any questions the patient may have about the study and will collect the patient's non-objection to participate in the study and their responses to the questionnaire.
Time frame: At enrolment
Percentage of patients whose employment was modified or discontinued due to PXE.
Time frame: At enrolment
Percentage of patients whose employment was modified or discontinued due to the vascular impact of PXE. Vascular impact will be assessed by their last Ankle Brachial Index measurement.
Time frame: At enrolment
Percentage of patients whose employment was modified or discontinued due to the visual impact of PXE. Visual impact will be assessed by their last Visual acuity measurement.
Time frame: At enrolment
Percentage of patients whose employment was modified or discontinued due to the skin impact of PXE. Skin impact will be assessed by the presence of skin damage due to PXE in the cervical and/or antecubital areas.
University Hospital, Angers
Other Gov
Employment Retention Issues for Patient With Pseudoxanthoma Elasticum
Acronym: MEE-PXE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05030831
ATP-Binding Cassette Subfamily C Member 6 Deficiency, Arterial calcification of infancy
Eatontown, New Jersey, United States
View Trial DetailsNCT05569252
Cardiovascular Diseases, Congenital Abnormalities
Bethesda, Maryland, United States
View Trial DetailsNCT05025722
Cardiovascular Diseases, Congenital Abnormalities
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT01525875
Calcinosis, Calcium Metabolism Disorders
New York, United States
View Trial Details